Get the Stockscreener App
21.51
0.70%
0.2268
Catalyst Pharmaceuticals Inc stock is traded at $21.51, with a volume of 124.15K.
It is up +0.70% in the last 24 hours and down -1.24% over the past month.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
See More
Previous Close:
$21.28
Open:
$21.12
24h Volume:
124.15K
Relative Volume:
0.10
Market Cap:
$2.62B
Revenue:
$460.48M
Net Income/Loss:
$142.80M
P/E Ratio:
18.23
EPS:
1.18
Net Cash Flow:
$221.79M
1W Performance:
+1.95%
1M Performance:
-1.24%
6M Performance:
-5.01%
1Y Performance:
+24.30%
1-Day Range:
$21.11
$21.55
1-Week Range:
$20.72
$21.64
52-Week Range:
$15.34
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
(305) 529-2522
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
21.48 | 2.56B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.85 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.38 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
393.95 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
679.77 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.16 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Robert W. Baird | Outperform |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Mar-14-24 | Initiated | Citigroup | Buy |
| Mar-07-24 | Initiated | BofA Securities | Buy |
| Dec-21-23 | Initiated | Oppenheimer | Outperform |
| Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Resumed | Piper Jaffray | Overweight |
| Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Sep-30-14 | Reiterated | ROTH Capital | Buy |
| Sep-16-14 | Reiterated | ROTH Capital | Buy |
| Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
| Oct-21-13 | Reiterated | Aegis Capital | Buy |
| Sep-24-13 | Initiated | Maxim Group | Buy |
| Sep-06-13 | Reiterated | Aegis Capital | Buy |
| Apr-18-13 | Initiated | Aegis Capital | Buy |
| Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
| May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
| May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
| Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
| Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
How many analysts rate Catalyst Pharmaceuticals Inc. as a “Buy”Free Stock Review Backed By Experts - jammulinksnews.com
How strong is Catalyst Pharmaceuticals Inc. company’s balance sheetAI Powered Review For 2025 - jammulinksnews.com
What is the dividend policy of Catalyst Pharmaceuticals Inc. stockAdvanced Screener Data Feed To Watch Now - jammulinksnews.com
What are analysts’ price targets for Catalyst Pharmaceuticals Inc. in the next 12 monthsStock Market Picks With High Returns - jammulinksnews.com
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Can Traders Expect Breakout From Catalyst Pharmaceuticals Inc. This WeekSmart Allocation Stock Pick Insights Gaining Interest - metal.it
Investors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have seen enviable returns of 404% over the past five years - Yahoo Finance
What makes Catalyst Pharmaceuticals Inc. stock price move sharplyReal Time Outlook With High Returns - jammulinksnews.com
What are the latest earnings results for Catalyst Pharmaceuticals Inc.Free Stock Market Forecast Reports - jammulinksnews.com
What catalysts could drive Catalyst Pharmaceuticals Inc. stock higher in 2025Rapid-fire capital growth - jammulinksnews.com
When is Catalyst Pharmaceuticals Inc. stock expected to show significant growthRetirement Planning Updates For Consistent Profits - jammulinksnews.com
Is Catalyst Pharmaceuticals Inc. stock overvalued or undervaluedRemarkable growth - jammulinksnews.com
Why is Catalyst Pharmaceuticals Inc. stock attracting strong analyst attentionExpert guidance for superior capital growth - jammulinksnews.com
What are the technical indicators suggesting about Catalyst Pharmaceuticals Inc.Capitalize on market trends early - jammulinksnews.com
How does Catalyst Pharmaceuticals Inc. compare to its industry peersAchieve superior returns with professional insights - jammulinksnews.com
What analysts say about Catalyst Pharmaceuticals Inc. stockExtraordinary profit generation - PrintWeekIndia
Is Catalyst Pharmaceuticals Inc. a good long term investmentMassive stock growth - Autocar Professional
Will Catalyst Pharmaceuticals Inc. stock split in the near futureSpectacular growth rates - jammulinksnews.com
What makes Catalyst Pharmaceuticals Inc. stock attractive to long term investorsRecord-breaking gains - jammulinksnews.com
What drives Catalyst Pharmaceuticals Inc. stock priceLightning-fast capital gains - Autocar Professional
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock - Yahoo Finance
Zacks.com featured highlights Catalyst Pharmaceuticals, SunOpta, Gambling.com and Orion Group - sharewise.com
Catalyst Pharmaceuticals Inc. Stock Analysis and ForecastFree Predictions - Autocar Professional
Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewswire
Catalyst Pharmaceuticals Scheduled to Release Q2 2025 Financial Results on August 6, 2025 - Nasdaq
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - Yahoo Finance
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Catalyst Pharmaceuticals Inc Stock (CPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sundaram Preethi | Chief Strategy Officer |
Jun 11 '25 |
Sale |
26.42 |
1,600 |
42,272 |
41,081 |
0.83%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):